Patent ID: 7625711
Filing Date: 2009-12-01
Classification: A61K,A61P,G01N

Abstract:
1. A method for screening a compound for development of a drug, said method comprising: (a) culturing a neuron expressing APP intracellular C terminal domains (AICD) and p53 in a culture medium that is supplemented with cisplatin, wherein said neuron is cultured (i) in the presence of a compound and (ii) in the absence of the compound, respectively, (b) homogenizing the neuron obtained in step (a) to form a cell lysate, (c) contacting the cell lysate with a first antibody, to form an AICD/p53/first antibody immune complex, wherein said first antibody is selected from the group consisting of an anti-AICD antibody and an anti-p53 antibody, (d) detecting and quantifying the AICD/p53/first antibody immune complex from step (c), (e) comparing the amount of the AICD/p53/first antibody immune complex formed in the absence of the compound with the amount of the AICD/p53/first antibody immune complex formed in the presence of the compound, and (f) selecting the compound that decreases the amount of the AICD/p53/first antibody immune complex compared to the amount of the AICD/p53/first antibody immune complex formed in the absence of the compound, wherein said decrease in the amount of the AICD/p53 complex is indicative of the compound inhibiting binding between AICD and p53.